A method for producing a fluorosulfonyl group-containing compound to obtain a compound represented by the following formula 5 from a compound represented by the following formula 1 as a starting material and a method for producing a fluorosulfonyl group-containing monomer in which the fluorosulfonyl group-containing compound is used:

##STR00001##

wherein R.sup.1 and R.sup.2 are a C.sub.1-3 alkylene group, and R.sup.F1 and R.sup.F2 are a C.sub.1-3 perfluoroalkylene group.

A method for producing a fluorosulfonyl group-containing compound to obtain a compound represented by the following formula 5 from a compound represented by the following formula 1 as a starting material and a method for producing a fluorosulfonyl group-containing monomer in which the fluorosulfonyl group-containing compound is used:

##STR00001##

wherein R.sup.1 and R.sup.2 are a C.sub.1-3 alkylene group, and R.sup.F1 and R.sup.F2 are a C.sub.1-3 perfluoroalkylene group.

A fluorosulfonyl group-containing polymer having units represented by the following formula u1, a sulfonic acid group-containing polymer having fluorosulfonyl groups in the fluorosulfonyl group-containing polymer converted into sulfonic acid groups, its production method and its applications:

##STR00001##

wherein R.sup.F1 and R.sup.F2 are a C.sub.1-3 perfluoroalkylene group.

A fluorosulfonyl group-containing polymer having units represented by the following formula u1, a sulfonic acid group-containing polymer having fluorosulfonyl groups in the fluorosulfonyl group-containing polymer converted into sulfonic acid groups, its production method and its applications:

##STR00001##

wherein R.sup.F1 and R.sup.F2 are a C.sub.1-3 perfluoroalkylene group.

Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with -lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

An iodine compound represented by formula (3) and a polymerization inhibitor including the iodine compound, wherein R.sup.21 to R.sup.25 are as defined herein, X.sup.1 is an n1-valent group, and n1 is an integer of 1 to 10: ##STR00001##

Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with -lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with -lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

A method for producing a fluorosulfonyl group-containing compound to obtain a compound represented by the following formula 5 from a compound represented by the following formula 1 as a starting material and a method for producing a fluorosulfonyl group-containing monomer in which the fluorosulfonyl group-containing compound is used: ##STR00001##
wherein R.sup.1 and R.sup.2 are a C.sub.1-3 alkylene group, and R.sup.F1 and R.sup.F2 are a C.sub.1-3 perfluoroalkylene group.

A method for producing a fluorosulfonyl group-containing compound to obtain a compound represented by the following formula 5 from a compound represented by the following formula 1 as a starting material and a method for producing a fluorosulfonyl group-containing monomer in which the fluorosulfonyl group-containing compound is used: ##STR00001##
wherein R.sup.1 and R.sup.2 are a C.sub.1-3 alkylene group, and R.sup.F1 and R.sup.F2 are a C.sub.1-3 perfluoroalkylene group.